The failure to reach an agreement comes despite a high-profile campaign by patient groups and ... recommend NHS funding in England and Wales for Enhertu (trastuzumab deruxtecan) as a second ...

(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive ...

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

The aim is to reverse NICE's decision not to recommend NHS funding in England and Wales for AstraZeneca and Daiichi Sankyo's HER2-targeted antibody-drug conjugate (ADC) Enhertu (trastuzumab ...